Dr. Erba on Unique Characteristics of CPX-351 in AML

Video

In Partnership With:

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Another characteristic of this formulation is that it targets the bone marrow and the leukemic blast, decreasing the off-target types of toxicity that occur, such as mucositis and alopecia, Erba explains. In the randomized phase II study—which led to the phase III study that was the basis for the FDA approval of CPX-351, patients were randomized to receive CPX-351 or 7+3. If they achieved remission they would then receive 2 cycles of CPX-351 at a lower dose or 2 cycles of daunorubicin plus cytarabine in a 2+5 schedule at a lower dose. Patients could then go on to receive stem cell transplant if they experienced a remission or at the physician's discretion.

Results showed that the primary endpoint was met; there was an improvement in overall survival (OS). The median OS with CPX-351 was 10 months, and was 6 months with 7+3.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD